Neostigmine-Atropine Combination Causes Stress Cardiomyopathy
- A recently documented case highlights a potential, though rare, adverse effect of combining the medications neostigmine and atropine.A previously healthy patient developed stress cardiomyopathy - also known as...
- Neostigmine and atropine are frequently used together in medical settings, especially during reversal of neuromuscular blockade after surgery or in the treatment of certain gastrointestinal conditions.
- The patient in this case exhibited symptoms consistent with stress cardiomyopathy shortly after receiving neostigmine and atropine.
Rare Cardiac Condition Triggered by Common Medications in Healthy Individual
Table of Contents
Published September 6, 2025
Stress Cardiomyopathy Linked too Neostigmine-Atropine Combination
A recently documented case highlights a potential, though rare, adverse effect of combining the medications neostigmine and atropine.A previously healthy patient developed stress cardiomyopathy – also known as takotsubo syndrome – following management of this drug combination. stress cardiomyopathy mimics a heart attack,causing temporary weakening of the heart muscle,but is frequently enough triggered by intense emotional or physical stress.
Neostigmine and atropine are frequently used together in medical settings, especially during reversal of neuromuscular blockade after surgery or in the treatment of certain gastrointestinal conditions. The combination aims to counteract the effects of muscle relaxants while minimizing unwanted side effects like excessive salivation or bradycardia (slow heart rate). However, this case suggests a possible link between the pharmacological interaction and the development of acute cardiac dysfunction.
Understanding the Patient Case
The patient in this case exhibited symptoms consistent with stress cardiomyopathy shortly after receiving neostigmine and atropine. Diagnostic tests, including an electrocardiogram (ECG) and echocardiogram, revealed characteristic patterns of the condition, such as temporary ballooning of the left ventricle. Cardiac biomarkers were also elevated, indicating myocardial injury.
Importantly, the patient had no prior history of heart disease or risk factors for cardiomyopathy. This suggests the medication combination was a significant contributing factor to the cardiac event. The patient ultimately recovered with supportive care, demonstrating the typically reversible nature of stress cardiomyopathy.
Implications and Future Research
While stress cardiomyopathy is generally considered benign and self-limiting, it can lead to serious complications, including heart failure and arrhythmias. This case report adds to a growing body of literature suggesting that certain medications, or combinations thereof, may act as triggers in susceptible individuals.
Healthcare professionals should be aware of this potential association and consider stress cardiomyopathy in the differential diagnosis of patients presenting with acute cardiac symptoms following neostigmine-atropine administration. Further research is needed to determine the underlying mechanisms responsible for this drug-induced cardiomyopathy and to identify individuals who might potentially be at increased risk. Vigilance and careful monitoring are crucial for patient safety.